MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil

Cancer Biology and Therapy

Volumn 9, Issue 7, 2010, Pages 514-522

  Hirai, Hiroshi ^a   Arai, Tsuyoshi ^a   Okada, Megumu ^a   Nishibata, Toshihide ^a   Kobayashi, Makiko ^a   Sakai, Naoko ^a   Imagaki, Kazuhide ^a   Ohtani, Junko ^a   Sakai, Takumi ^a   Yoshizumi, Takashi ^a   Mizuarai, Shinji ^a   Iwasawa, Yoshikazu ^a   Kotani, Hidehito ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 FU; Checkpoint; DNA damaging agents; Kinase inhibitor; MK 1775; Wee1

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL)PYRIDIN 2 YL] 6 [[4 (4 METHYLPIPERAZIN 1 YL)PHENYL]AMINO] 1,2 DIHYDRO 3H PYRAZOLO[3,4 D]PYRIMIDIN 3 ONE; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HISTONE H3; MITOMYCIN C; MK 1775; PEMETREXED; PROTEIN; PROTEIN INHIBITOR; PROTEIN WEE1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT;

EID: 77953711939     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.7.11115     Document Type: Article

References (32)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-20.
2. Zhou BBS, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Rev Cancer 2004; 4:1-10.
3. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73:39-85.
4. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000; 33:261-74.
5. 2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513-9.
6. 2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-8.
7. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13:1955-60.
8. cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257:1955-7.
9. +-like gene in human cells. Nature 1991; 353:80-3.
10. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EBMO J 1995; 14:1878-91.
11. cdc2 exclusively on Tyr15. EBMO J 1993; 12:75-85.
12. 2 arrest in human cells. J Cell Biol 1996; 134:963-70.
13. 2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16:545-54.
14. 2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3:305-13.
15. 2 checkpoint abrogator. Cancer Res 2001; 61:8211-7.
16. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992-3000.
17. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8.
18. Chua YJ, Zalcberg JR. Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther 2008; 8:595-604.
19. Onodera H, Kuruma I, Ishitsuka H, Horii I. Pharmacokinetic study of capecitabine in monkeys and mice; species differences in distribution of the enzymes responsible for its activation to 5-FU. Xenobio Metabol and Dispos 2000; 15:439-51.
20. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 2002; 7:11-7.
21. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 2009; 18:335-48.
22. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005; 24:1403-11.
23. Xiao Z, Xue J, Sowin TJ, Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2 and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006; 5:1935-43.
24. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008; 7:2394-404.
25. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66.
26. Matthews DJ, Yakes FM, Chen J, Tadano M, Bomheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the antitumor activity of gemcitabine in vivo. Cell Cycle 2007; 6:104-10.
27. Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N, et al. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 2005; 55:12-20.
28. Suardet L, Li C, Little JB. Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. Int J Cancer 1996; 68:126-31.
29. Liu Y, Bodmer WF. Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 2006; 103:976-81.
30. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeler E, Zhu H, et al. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 2009; 69:984-91.
31. Peters GJ, van Triest B, Backus HHJ, Kuiper CM, van der Wilt CL, Pinedo HM. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 2000; 36:916-24.
32. Sagulenko E, Savelyeva L, Ehemann V, Sagulenko V, Hofmann W, Arnold K, et al. Suppression of polyploidy by the BRCA2 protein. Cancer Lett 2007; 257:65-72.